A STABILISED-RELEASE NEUROPEPTIDE FUNCTIONS AS A NOVEL CUTANEOUS ANTI-FIBROTIC AGENT

被引：0
|
作者：
Woloszynek, J. [1 ]
Etzel, K. [1 ]
Vernes, J.
McIntosh, D. [2 ]
Moore, C. [3 ]
Haq, M. [4 ]
Lopez, H. [1 ]
Haq, S. [5 ]
机构：
[1] Murigenics, Vallejo, CA USA
[2] Daval Int Ltd, Eastbourne, England
[3] Portsmouth Hosp, Portsmouth, Hants, England
[4] Maidstone & Tonbridge Hosp, Maidstone, Kent, England
[5] Daval Int Ltd, Med, Eastbourne, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.5868
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0213
引用
收藏
页码：874 / 874
页数：1
相关论文
共 50 条
  • [21] A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat
    Gilbert, Richard E.
    Zhang, Yuan
    Williams, Spencer J.
    Zammit, Steven C.
    Stapleton, David I.
    Cox, Alison J.
    Krum, Henry
    Langham, Robyn
    Kelly, Darren J.
    PLOS ONE, 2012, 7 (10):
  • [22] Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives
    Sassoli, Chiara
    Nistri, Silvia
    Chellini, Flaminia
    Bani, Daniele
    CURRENT MOLECULAR MEDICINE, 2022, 22 (03) : 196 - 208
  • [23] A case of atypical localized scleroderma presenting with pseudoainhum: Treatment with tranilast, an anti-fibrotic agent
    Tajima, S
    Suzuki, Y
    Inazumi, T
    ACTA DERMATO-VENEREOLOGICA, 1996, 76 (02) : 162 - 162
  • [24] Effectiveness of aspartate of adenosine as hepatoprotective and anti-fibrotic agent as compared with the parental adenosine.
    Hernandez-Munoz, R
    HEPATOLOGY, 2003, 38 (04) : 700A - 701A
  • [25] A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
    McPherson, Stuart
    Wilkinson, Nina
    Tiniakos, Dina
    Wilkinson, Jennifer
    Burt, Alastair D.
    McColl, Elaine
    Stocken, Deborah D.
    Steen, Nick
    Barnes, Jane
    Goudie, Nicola
    Stewart, Stephen
    Bury, Yvonne
    Mann, Derek
    Anstee, Quentin M.
    Day, Christopher P.
    PLOS ONE, 2017, 12 (04):
  • [26] A semi-parametric analysis for identifying Scleroderma patients responsive to an anti-fibrotic agent
    Li, Jialiang
    Wong, Weng Kee
    CONTEMPORARY CLINICAL TRIALS, 2009, 30 (02) : 105 - 113
  • [27] Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
    Andersen, Stine
    Axelsen, Julie Birkmose
    Ringgaard, Steffen
    Nyengaard, Jens Randel
    Nielsen, Signe Holm
    Genovese, Federica
    Karsdal, Morten Asser
    Hyldebrandt, Janus Adler
    Sorensen, Charlotte Brandt
    de Man, Frances S.
    Bogaard, Harm Jan
    Nielsen-Kudsk, Jens Erik
    Andersen, Asger
    PULMONARY CIRCULATION, 2019, 9 (02)
  • [28] Anti-inflammatory and anti-fibrotic effects of novel peptide GQDGLAGPK in alkaline burns rabbit
    Iin, Lee Yoon
    Lee, Hye Sook
    Lee, YuJin
    Yang, JaeWook
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [29] GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
    Speca, Silvia
    Dubuquoy, Caroline
    Rousseaux, Christel
    Jadot, Elodie
    Desreumaux, Pierre
    Spagnolo, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [30] Therapeutic Targeting Of Fibroblast Durotaxis: A Novel Class Of Anti-Fibrotic Therapies For Ipf
    Lagares, D.
    Grasberger, P.
    Probst, C.
    Engler, A.
    Tager, A. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
12345